Mus vs Saudi Arabia: HIV-positive TB patients on ART (antiretroviral therapy)
Mus
100.0%
in 2024
Saudi Arabia
100.0%
in 2024
Mus rank
1st
Saudi Arabia rank
1st
HIV-positive TB patients on ART (antiretroviral therapy) over time
- Mus
- Saudi Arabia
How they compare
Mus currently reports 100.0% against 100.0% in Saudi Arabia, a difference of 0.0%.
Across all 11 years both countries report, Saudi Arabia has been ahead every year.
Mus ranks 1st and Saudi Arabia ranks 1st of 2 regions.
Saudi Arabia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Mus | Saudi Arabia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 68.0% | 100.0% | 32.0% | Saudi Arabia |
| 2010s | 83.8% | 99.0% | 15.2% | Saudi Arabia |
| 2020s | 100.0% | 100.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv-positive tb patients on art (antiretroviral therapy), Mus or Saudi Arabia?
- Mus, at 100.0% against 100.0% in Saudi Arabia as of 2024.
- What is the difference in hiv-positive tb patients on art (antiretroviral therapy) between Mus and Saudi Arabia?
- 0.0%, with Mus ahead.
- How many years of comparable data are there for Mus and Saudi Arabia?
- 11 years are reported by both, from 2007 to 2024.
- How do Mus and Saudi Arabia rank globally for hiv-positive tb patients on art (antiretroviral therapy)?
- Mus ranks 1st and Saudi Arabia ranks 1st of 2 regions.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.